v3.25.2
SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of financial information with respect to single operating segment
 
   
Six months ended
June 30,
 
   
2025
   
2024
 
   
Unaudited
 
   
$
   
$
 
Total Revenues
   
3,541
     
9,261
 
                 
Less:
               
          R&D expenses
               
               Preclinical
   
6,659
     
8,546
 
               Clinical
   
6,982
     
7,107
 
           SG&A
   
4,851
     
4,592
 
           Financial income, net
   
(2,314
)
   
(2,528
)
           Taxes on income
   
14
     
14
 
           Other segment expenses*
   
1,872
     
920
 
                 
Net loss
   
(14,523
)
   
(9,390
)
 
*Other segment expense (income) during the six months ended June 30, 2025 and 2024 includes property and equipment depreciation, GS-0321 asset of set-up activities, share-based compensation and other adjustments.
Schedule of total revenues and long-lived assets by geographic area
   
Six months ended
June 30,
 
   
2025
   
2024
 
   
Unaudited
 
Revenue from sales to customers:
           
             
United States
 
$
3,541
   
$
4,261
 
Europe
   
-
     
5,000
 
                 
Total revenues
 
$
3,541
   
$
9,261